Quantum Biopharma (QNTM) Receivables - Net (2018 - 2025)

Quantum Biopharma has disclosed Receivables - Net across 8 years of filings, most recently posting $231053.0 for Q4 2025.

• Receivables - Net for Q4 2025 came in at $231053.0, down 38.33% year-over-year; the trailing twelve-month figure through Dec 2025 was $231053.0 (down 38.33% YoY), and the FY2025 annual result was $231053.0, down 38.33% from the prior year.
• Receivables - Net came in at $231053.0 for Q4 2025 at Quantum Biopharma, down from $374678.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $500964.0 in Q4 2021 to a low of -$341916.0 in Q2 2021.
• The 5-year median for Receivables - Net is $229908.5 (2023), against an average of $138364.0.
• Peak annual rise in Receivables - Net reached 210.5% in 2021, while the deepest fall reached 170.39% in 2021.
• Quantum Biopharma's Receivables - Net stood at $500964.0 in 2021, then dropped by 25.27% to $374377.0 in 2022, then slumped by 38.89% to $228764.0 in 2023, then soared by 63.78% to $374678.0 in 2024, then slumped by 38.33% to $231053.0 in 2025.
• The last three Receivables - Net figures came in at $231053.0 (Q4 2025), $374678.0 (Q4 2024), and $228764.0 (Q4 2023), per Business Quant data.